Averting opioid trial, Teva, drug distributors reach last-gasp settlement
Under the agreement, Teva would donate Suboxone tablets up to the amount needed to meet the majority of the currently estimated US patient need over the next 10 years, valued at approximately $23b.
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019(photo credit: AMIR COHEN/REUTERS)ByREUTERS, EYTAN HALON